A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly)

Annals of Oncology

Volumn 16, Issue 1, 2005, Pages 124-131

  Ballova, V ^a   Ruffer J U ^a   Haverkamp, H ^a   Pfistner, B ^a   Muller Hermelink H K ^b   Duhmke E ^c   Worst, P ^d   Wilhelmy, M ^e   Naumann, R ^f   Hentrich, M ^g   Eich, H T ^a   Josting, A ^a   Loffler M ^h   Diehl, V ^a   Engert, A ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e VIVANTES KLINIKUM NEUKÖLLN   (Germany)

^f UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^g Harlaching Hospital   (Germany)

^h UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

BEACOPP; Chemotherapy; Elderly patients; Hodgkin's lymphoma

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ADVANCED CANCER; AGE DISTRIBUTION; AGED; ALOPECIA; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG FATALITY; FEMALE; FEVER; FOLLOW UP; GASTROINTESTINAL DISEASE; HODGKIN DISEASE; HUMAN; INFECTION; INTERMETHOD COMPARISON; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; MUCOSA INFLAMMATION; NAUSEA; NEUROTOXICITY; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SECOND CANCER; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT FAILURE;

ADMINISTRATION, ORAL; AGED; AGING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; FEMALE; HODGKIN DISEASE; HUMANS; INFUSIONS, INTRAVENOUS; PREDNISONE; PROCARBAZINE; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VINBLASTINE; VINCRISTINE;

EID: 19944428790     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdi023     Document Type: Article

References (40)

1. Peterson BA, Pajak TF, Cooper MR et al. Effect of age on therapeutic response and survival in advanced Hodgkin's disease. Cancer Treat Rep 1982; 66: 889-898.
2. Austin-Seymour MM, Hoppe RT, Cox RS et al. Hodgkin's disease in patients over sixty years old. Ann Intern Med 1984; 100: 13-18.
3. Walker A, Schoenfeld E, Lowman JT et al. Survival of the older patients compared with the younger patient with Hodgkin's disease. Cancer 1990; 65: 1635-1640.
4. Wendelin C, Björkholm M, Biberfeld P et al. Prognostic factors in Hodgkin's disease with special reference to age. Cancer 1984; 53: 1202-1208.
5. Bennett JM, Andersen JW, Begg CB et al. Age and Hodgkin's disease: the impact of competing risks and possibility salvage therapy on long term survival: an ECOG study. Leuk Res 1993; 17: 825-832.
6. Diaz-Pavon JR, Cabanillas F, Majlis A et al. Outcome of Hodgkin's disease elderly patients. Hematol Oncol 1995; 13: 19-24.
7. Specht L, Nissen NI. Hodgkin's disease and age. Eur J Haematol 1989; 43: 127-135.
8. Levis A, Depaoli L, Urgesi A et al. Probability of cure in elderly Hodgkin's disease patients. Haematologica 1994; 79: 46-54.
9. Erdkamp FL, Breed WP, Bosch LJ et al. Hodgkin's disease in the elderly. Cancer 1992; 70: 830-834.
10. Stark GL, Wood KM, Jack F et al. Hodgkin's disease in the elderly: a population-based study. Br J Haematol 2002; 119: 432-440.
11. Kim HK, Silver B, Li S et al. Hodgkin's disease in elderly patients (≥60): Clinical outcome and treatment strategies. Int J Radiat Oncol Biol Phys 2003; 56: 556-560.
12. Bosi A, Ponticelli P, Casini C et al. Clinical data and therapeutic approach in elderly patients with Hodgkin's disease. Haematologica 1989; 74: 463-473.
13. Van Spronsen DJ, Janssen-Heijnen MLG, Breed WPM et al. Prevalence of co-morbidity and its relationship to treatment among unselected patients with Hodgkin's disease and non-Hodgkin's lymphoma, 1993-1996. Ann Hematol 1999; 78: 315-319.
14. Enblad G, Glimelius B, Sundstrom C. Treatment outcome in Hodgkin's disease in patients above the age of 60: A population-based study. Ann Oncol 1991; 2: 297-302.
15. Hudson V, MacLennan KA, Easterling MJ et al. The prognostic significance of age in Hodgkin's disease: examination of 1500 patients (BNLI report no. 23). Clin Radiol 1983; 34: 503-506.
16. Guinee VF, Geoffrey GC, Durand M et al. The prognosis of Hodgkin's disease in older adults. J Clin Oncol 1991; 9: 947-953.
17. Canellos GP, Anderson JR, Propert KJ et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992; 327: 1478-1484.
18. Rüffer JU, Schiller P, Sieber M et al. Hodgkin's lymphoma in the elderly - experience of the GHSG. Leuk Lymphoma 2001; 42 (Suppl 2): 103 (Abstr P-230).
19. Horning SJ, Hoppe RT, Breslin S et al. Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: Mature results of prospective clinical trial. J Clin Oncol 2002; 20: 630-637.
20. Connors JM, Klimo P, Adams G et al. Treatment of advanced Hodgkin's disease with chemotherapy - comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD. A report from the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1997; 15: 1638-1645.
21. Somers RS, Carde P, Henry-Amar M et al. A randomized study in stage III.B and IV Hodgkin's disease comparing eight courses of MOPP versus an alternation of MOPP with ABVD: A European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie controlled clinical trial. J Clin Oncol 1994; 12: 279-287.
22. Glick JH, Young ML, Harrington D et al. MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure free and overall survival: The 8-year results of the intergroup trial. J Clin Oncol 1998; 16: 19-26.
23. Brice P, Colin P, Berger F et al. Advanced Hodgkin disease with large mediastinal involvement can be treated with eight cycles of chemotherapy alone after a major response to six cycles of chemotherapy. Cancer 2001; 92: 453-459.
24. Mir R, Anderson J, Strauchen J et al. Hodgkin's disease in patients 60 years of age or older. Histologic and clinical features of advanced-stage disease. Cancer 1993; 71: 1857-1866.
25. Levis A, Depaoli L, Bertini M et al. Results of a low aggressivity chemotherapy regimen (CVP/CEB) in elderly Hodgkin's disease patients. Haematologica 1996; 81: 450-456.
26. Levis A, Anselmo AP, Ambrosetti A et al. VEPEMB chemotherapy in elderly Hodgkin lymphoma patients. Results from an Intergruppo Italiano Linfomi (IIL) study. Ann Oncol 2004; 15: 123-128.
27. Macpherson N, Klasa RJ, Gascoyne R et al. Treatment of elderly Hodgkin's lymphoma patients with a novel 5-drug regimen (ODBEP): A phase II study. Leuk Lymphoma 2002; 43: 1395-1402.
28. Duggan DB, Petroni FR, Johnson JL et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's Disease: report of an intergroup trial. J Clin Oncol 2003; 21: 607-614.
29. Diehl V, Sieber M, Ruffer U et al. BEACOPP: An intensified chemotherapy regimen in advanced Hodgkin's disease. Ann Oncol 1997; 8: 143-148.
30. Diehl V, Franklin J, Pfreunschuh M et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP/ABVD for advanced Hodgkin's disease. N Engl J Med 2003; 348: 2386-2395.
31. Loeffler M, Diehl V, Pfreundschuh M et al. Dose-response relationship of complementary radiotherapy following four cycles of combination chemotherapy in intermediate-stage Hodgkin's disease. J Clin Oncol 1997; 15: 2275-2287.
32. Hasenclever D, Diehl V, Armitage JO et al. A prognostic score for advanced Hodgkin's disease. N Engl J Med 1998; 339: 1506-1514.
33. Rossi-Ferrini P, Bosi A, Casini C et al. Hodgkin's disease in the elderly: a retrospective clinicopathological study of 61 patients aged over 60 years. Acta Haematol 1987; 78: 163-170.
34. Landgren O, Algernon C, Axdorph U et al. Hodgkin's lymphoma in the elderly with special reference to type and intensity of chemotherapy in relation to prognosis. Haematologica 2003; 88: 438-444.
35. Weeks CD, Vose JM, Lynch JC et al. Hodgkin's disease in the elderly: improved treatment outcome with a doxorubicin-containing regimen. J Clin Oncol 2002; 20: 1087-1093.
36. Engel C, Loeffler M, Schmitz S et al. Acute hematologic toxicity and practicability of dose-intensified BEACOPP chemotherapy for advanced stage Hodgkin's disease. Ann Oncol 2000; 11: 1105-1114.
37. Diehl V, Franklin J, Hasenclever D et al. BEACOPP, a new dose escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: Interim report from a trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 1998; 16: 3810-3821.
38. Radford JA, Rohatiner AZ, Ryder WD et al. ChlVPP/EVA hybrid versus the weekly VAPEC-B regimen for previously untreated Hodgkin's disease. J Clin Oncol 2002; 20: 2988-2994.
39. Doorduijn JK, van der Holt B, van Imhoff GW et al. CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma. J Clin Oncol 2003; 16: 3041-3050.
40. Bohlius J, Reiser M, Schwarzer G et al. Impact of granulocyte colony-stimulating factor (CSF) and granulocyte-macrophage CSF in patients with malignant lymphoma: a systematic review. Br J Haematol 2003; 122: 413-423.